bioAffinity Technologies Reports Q3 2026 Results
bioAffinity Technologies reported Q3 2026 revenue of $1.07 million, down 26% year-over-year from $1.45 million in Q3 2025, due primarily to decreased average reimbursement per CyPath Lung test. The company reported a net loss of $5.28 million compared to a net loss of $5.05 million in the prior-year quarter. Cash and cash equivalents were $2.55 million as of September 30, 2026, down from $6.45 million at December 31, 2025.
Key takeaways
Revenue decreased 26% year-over-year to $1.07 million in Q3 2026 due to lower average reimbursement per CyPath Lung test
Net loss widened to $5.28 million from $5.05 million in Q3 2025, with operating loss increasing to $3.51 million from $2.29 million
CyPath Lung unit sales increased 100% year-to-date through Q3 2026 compared to the first nine months of 2025
Testing revenue for the first nine months of 2026 increased 79% to approximately $1.1 million compared to the same period in 2025
Operating expenses increased 23% year-over-year to $4.58 million, driven by additional sales and marketing personnel and clinical trial costs
The company expanded its government healthcare distribution network through an agreement with AvMEDICAL to serve VA and other government agencies
Cash position declined to $2.55 million as of September 30, 2026, with approximately $4.0 million raised in financing subsequent to quarter-end
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.